hyperlipidemia dan o’connell, md montefiore family medicine august 2004
TRANSCRIPT
RISKS TO HEALTH
• Hyperlipidemia
• Hypertension
• Diabetes
• Coronary Artery Disease
• Congestive Heart Failure
Natural History of Insulin Resistance• Age 15 Acanthosis nigrans • Age 23 ? PCO –insulin resistance, irreg period, irregular
period, hirsutism, obesity • Age 25 Dyslipidemia - HDL , Trig• Age 30 Gestational DM• Age 35 Hyperglycemia• Age 40 Diabetes• Age 45 Metabolic syn - HTN,DM, dyslipidemia, obesity• Age 55 – Acute MI• Age 58 Renal insufficiency, renal failure• Age 61 vision loss, neuropathy, toe amputation• Age 62 – Claudication 2nd PVD, small CVAs• Age 63 - CHF
PRE -JULY 2004
0 RISK >2 risk factors
CAD or equiv
3-6 mo diet lifestyle modification
160-190 130-160 100-130
Medication >190
GOAL <160
>160
GOAL <130
>130
GOAL <100
AFTER JULY 2004
0 RISK >2 risk factors
CAD or equiv
3-6 mo diet lifestyle modification
160-190 130-160 70-100
Medication >190
GOAL <160
>160
GOAL <130
>100
GOAL <70
CAD EquivalentsAKA atherosclerosis
• Peripheral Vascular Disease
• Cerebral Vascular Disease
• Diabetes (based on 10 yr MI risk equiv of active CAD)
The Nordin Rule?
• “What do you think is the best goal for LDL?”
• “It should be less than the HDL.”
STATINS• HMG CoA Reductase inhibitors
• Atorvastatin (lipitor)• Simvastatin (zocor)• Pravastatin (pravachol)• Lovastatin (mevacor)• Fluvastatin (lescol)• Rosuvastatin (crestor)
• Risk – elevated LFTs, rhabdo ( CPK)
CASE 1 elevated LDL
• 42 yo in good health, no tob, no FMH
• Chol 279
• LDL 185
• HDL 45
• Trig 135
CASE 1 elevated LDL
• 42 yo – after 2 mo diet, exercise
• Chol 289
• LDL 195
• HDL 45
• Trig 135
Case 2 - LIPIDS
• 51 yo HTN, Quit tob last yr p 20 pk-yrs, FMH neg
• CHOL 260
• LDL 155
• HDL 35
• TRIG 240
NON-HDL CHOLESTEROL
• Useful when triglycerides very high and LDL cannot be measured
• Normal triglyceride levels usually contribute 30 points to cholesterol
• Can calculate “treatable LDL” by: Non-HDL chol = (Total chol) – HDL LDLeq = Non HDL CHOL – 30 OR
• LDLeq = (CHOL – HDL) - 30
DYDSLIPIDEMIA
• Trends in MI – CAD decreasing thru past 50 years, but now DM rapidly increasing
• 20th century heart attack – HIGH LDL The beef and+tobacco MI
• 21st century MI – LOW HDL, DIABETIC MI The insulin resistant metabolic syndrome MI
Low HDL/ high triglycerides
• Fewer studies on morbidity mortality
• Statins increase 5-15%
• Niacin (Niaspan, slo-niacin) increase 10-20%
LIPIDS – case 3
• 62 yo DM, HTN, on Zocor 40
• CHOL 160
• LDL 95, HDL 50, trig 100
• SGOT/SGPT 110/90 CPK 150
Other lipid meds• Fibrates – lower triglycerides • Gemfibrazole (lopid) 600 bid• Fenfibrate (tricor) – fewer interaction with Statin then
gemfibrazole
• Niacin 250mg – 4000 mg qd – raise HDL• Causes flushing 15-30 min• Slo-niacin , niaspan
• Zetia 10 mg (ezetimibe) – decreased absorbtion Adjunct to statin, or when liver or rhabdo effects 2-5 YEAR RULE!!
•
Low risk patients Scotland trial, ’96, coronary events measured
• Measured MI, death, CVA placebo vs statin
• No treatment 248/3210 =7.7%• Treatment (pravastatin 174/3260 = 5.3%
• RRR?• ARR?• NNTT?
Low risk patients Scotland trial, ’96, coronary events measured
• No treatment 248/3210 = 7.7%
• Treatment (pravastatin) 174/3264 = 5.3%
• RRR 31%
• ARR 2.4%
• NNTT 100/2.4 = 42
Hyperlipidemia – effect of lifestyle change
• Low sat fat• Whole grains, oats, barley (soluble fiber) 10 gm • Plant sterols (Benachol margarine) 2gm• Almonds 1 oz (30gm)• Soy protein 20 gm
• 30% reduction in LDL (equivalent to statins)
• JAMA 7/23-30/03
PROVE-IT study• Patients admitted for acute coronary syndrome
• Pravachol 40 (standard) vs Lipitor 80 (intensive)
Coronary events (death, MI, CVA)
• Lipitor 22.4%
• Pravachol events 26.3%
PROVE-IT – COST ANALYSIS
• Lipitor 22.4% $1400/yr
• Pravachol 26.3% $900/yr
• ? Cost per avoided event
NNTT- assuming 30% reduction
CAD risk With RX ARR NNTT= 1/ARR
8% 5.6% 2.4% 42
10% 7% 3% 33
15% 10.5% 4.5% 22
20% 14% 6% 17
50% 35% 15% 7
Pediatric hyperlipidemia
• As per NCEP
• Diet therapy for LDL > 130
• For > age 10 , consider medication if >190 after 6 mo diet RX
Statins• HMG coA Reductase inhibitors• 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
• Statins block (inhibit) an enzyme the body needs to produce cholesterol. As a result, LDL cholesterol levels in the blood go down, thereby lowering total blood cholesterol levels.
• Statins may also affect levels of certain clotting factors in the blood and lower the risk of clot formation. Lowering the risk of clot formation is important because clots can lead to heart attack or stroke. Statins also have anti-inflammatory effects that may help reduce the risk of coronary artery disease (CAD).
Statins• Lower LDL 20-60%• Elevate HDL 5-15%
• Studies with Pravastatin, simvastatin, lovastatin show 30-40% decrease in mortality from MI in pts with CAD
• Lipids return to baseline level 2-3 wks after d/c
Statins
• Most common side effects :Nausea, diarrhea, constipation, muscle ache, elevated LFTs (1-2%)
• Fatigue, loss of sense of well being at high doses
• Increased liver toxicity together with gemfibrazole or niacin
• Pravastatin not eliminated by P-450, less rhabdomyalysis
• Cerivastatin (Baycol)withdrawn from market 2001 due to 10x increased incidence of rhabdo, cases of renal failure
Statins
• Monitor LFTs at 6-12 weeks, then q6-12 mo if normal, or when other new medication added
• Document if no muscle ache; if + muscle ache, check CPK